210 related articles for article (PubMed ID: 37335420)
1. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
[TBL] [Abstract][Full Text] [Related]
2. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
3. Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
Silva RS; Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
Cell Biol Int; 2018 Aug; 42(8):1006-1020. PubMed ID: 29603508
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
[TBL] [Abstract][Full Text] [Related]
5. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
[TBL] [Abstract][Full Text] [Related]
7. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
9. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
11. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
Alves LF; da Silva RF; Cagnon VHA
Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
[TBL] [Abstract][Full Text] [Related]
14. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
16. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
18. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
[TBL] [Abstract][Full Text] [Related]
19. Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
Prostate; 2017 Jun; 77(8):838-848. PubMed ID: 28191652
[TBL] [Abstract][Full Text] [Related]
20. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction.
Tang SN; Zhang J; Jiang P; Datta P; Leitzman P; O'Sullivan MG; Jiang C; Xing C; Lü J
Mol Carcinog; 2016 Dec; 55(12):2291-2303. PubMed ID: 26840761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
